# Replagal Enzyme Replacement Therapy for Children With Fabry Disease

> **NCT00084084** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 17 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Agalsidase alfa

## Key facts

- **NCT ID:** NCT00084084
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-10
- **Primary completion:** 2011-06-15
- **Final completion:** 2011-06-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084084, "Replagal Enzyme Replacement Therapy for Children With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00084084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*